Cargando…

Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors

Detalles Bibliográficos
Autores principales:	Waissengrin, Barliz, Agbarya, Abed, Safadi, Esraa, Padova, Hagit, Wolf, Ido
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016402/ https://www.ncbi.nlm.nih.gov/pubmed/33812495 http://dx.doi.org/10.1016/S1470-2045(21)00155-8

Ejemplares similares

Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer
por: Ligumsky, Hagai, et al.
Publicado: (2022)

Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients
por: Ligumsky, Hagai, et al.
Publicado: (2021)

Short-Term Safety of Booster Immunization With BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers
por: Paran, Yael, et al.
Publicado: (2021)

Safety and BNT162b2 mRNA COVID-19 vaccination
por: Joob, Beuy, et al.
Publicado: (2021)

Effectiveness of BNT162b2 against COVID-19 in adolescents
por: Powell, Annabel A, et al.
Publicado: (2022)

Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT
por: Redjoul, Rabah, et al.
Publicado: (2021)

Efficacy of the mRNA-Based BNT162b2 COVID-19 Vaccine in Patients with Solid Malignancies Treated with Anti-Neoplastic Drugs
por: Agbarya, Abed, et al.
Publicado: (2021)

Effect of cannabis on oxaliplatin-induced peripheral neuropathy among oncology patients: a retrospective analysis
por: Waissengrin, Barliz, et al.
Publicado: (2021)

Artificial intelligence (AI) molecular analysis tool assists in rapid treatment decision in lung cancer: a case report
por: Waissengrin, Barliz, et al.
Publicado: (2023)

Response to “Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: Report of 5 cases”
por: Lim, Ziying Vanessa, et al.
Publicado: (2022)

Beta SARS-CoV-2 variant and BNT162b2 vaccine effectiveness in long-term care facilities in France
por: Lefèvre, Benjamin, et al.
Publicado: (2021)

Reassurance on bleeding and thrombotic events following second dose BNT162b2 and ChAdOx1 COVID-19 vaccines
por: Pavord, Sue, et al.
Publicado: (2023)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
por: Polack, Fernando P., et al.
Publicado: (2020)

Heterologous ChAdOx1-nCoV19–BNT162b2 vaccination provides superior immunogenicity against COVID-19
por: Richardson, Christopher D
Publicado: (2021)

Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Melanoma Treated with Immunotherapy
por: Diamantopoulos, Panagiotis T., et al.
Publicado: (2022)

Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes
por: Karavani, Gilad, et al.
Publicado: (2022)

Comment on Aldén et al. Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line. Curr. Issues Mol. Biol. 2022, 44, 1115–1126
por: Merchant, Hamid A.
Publicado: (2022)

Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents
por: June Choe, Young, et al.
Publicado: (2022)

Are we over-treating with checkpoint inhibitors?
por: Danson, Sarah, et al.
Publicado: (2019)

Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
por: Barda, Noam, et al.
Publicado: (2021)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Impact of tozinameran (BNT162b2) mRNA vaccine on kidney transplant and chronic dialysis patients: 3–5 months follow-up
por: Ben-Dov, Iddo Z., et al.
Publicado: (2022)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
por: Thomas, Stephen J., et al.
Publicado: (2021)

Safety of the BNT162b2 mRNA COVID-19 vaccine in patients with familial Mediterranean fever
por: Shechtman, Liran, et al.
Publicado: (2022)

Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
por: Benjamini, Ohad, et al.
Publicado: (2021)

Safety of BNT162b2 mRNA COVID-19 vaccine in patients with mast cell disorders
por: Rosman, Yossi, et al.
Publicado: (2021)

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments
por: Agbarya, Abed, et al.
Publicado: (2023)

Predictors of Immunogenic Response to the BNT162b2 mRNA COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases Treated with Rituximab
por: Furer, Victoria, et al.
Publicado: (2022)

Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [(18)F]FDG PET-CT and relevance to study interpretation
por: Cohen, Dan, et al.
Publicado: (2021)

Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients—An Italian Single-Center Experience
por: Persano, Irene, et al.
Publicado: (2023)

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1
por: Levy, Itzchak, et al.
Publicado: (2021)

The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients
por: Zitt, Emanuel, et al.
Publicado: (2021)

Immunogenicity and safety of the mRNA-based BNT162b2 vaccine in systemic autoimmune rheumatic diseases patients
por: Pri-Paz Basson, Yael, et al.
Publicado: (2022)

Safety of mRNA COVID-19 vaccines during pregnancy
por: Ellington, Sascha, et al.
Publicado: (2022)

Safety and reactogenicity of second booster doses for mRNA vaccines
por: Wilder-Smith, Annelies, et al.
Publicado: (2023)

Consecutive BNT162b2 mRNA vaccination induces short-term epigenetic memory in innate immune cells
por: Yamaguchi, Yuta, et al.
Publicado: (2022)

Comparison of mRNA Vaccinations with BNT162b2 or mRNA-1273 in Anti-CD20-Treated Multiple Sclerosis Patients
por: Hammer, Helly, et al.
Publicado: (2022)

BNT162b2 mRNA COVID-19 Vaccine: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

Delayed large pruritic eruption to the BNT162b2 mRNA vaccine
por: Terashima, Takeshi
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1csjr65jqqq2avqj0gfe4a2kbc